活性蓝2 | 79241-87-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 中文名称: 活性蓝2
• 中文别名: 汽巴蓝/兰色染料；汽巴蓝F3GA；兰色染料
• 英文名称: Reactive blue 2
• 英文别名: 1-amino-4-((4-((6-chloro-4-((3-sulfophenyl)imino)-3,4-dihydro-1,3,5-triazin-2(1H)-ylidene)amino)-3-sulfophenyl)amino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid；1-amino-4-[4-[[6-chloro-4-(3-sulfophenyl)imino-1H-1,3,5-triazin-2-ylidene]amino]-3-sulfoanilino]-9,10-dioxoanthracene-2-sulfonic acid
• CAS: 79241-87-5
• 化学式: C₂₉H₂₀ClN₇O₁₁S₃
• 分子量: 774.169
• InChiKey: JQYMGXZJTCOARG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  51
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  323
• 氢给体数：
  7
• 氢受体数：
  18

反应信息

• 作为产物：
  描述：

  1-氨基-4-(4-氨基-3-磺基苯胺基)-9,10-二氢-9,10-二氧代蒽-2-磺酸 在 sodium carbonate 作用下， 以 水 、 丙酮 为溶剂， 反应 3.0h， 生成 活性蓝2
  参考文献：
  名称：

  Constitutional isomers of Reactive Blue 2 – selective P2Y-receptor antagonists?

  摘要：

  The anthraquinone derivative Reactive Blue 2 (RB 2) is one of the most widely used P2-receptor antagonists, still claimed to be P2Y-selective. RB 2 is defined as a mixture of two constitutional isomers and commercially available in different identity and purity. A sample of RB 2, offered for sale by RBI, purchased from Biotrend, Koln, Germany, was chromatographically purified and identified by H-1- and C-13-NMR studies as a 35:65 mixture of the terminal ring F meta and para constitutional isomers. The two constitutional isomers of RB 2 were synthesised and tested alongside with the ortho isomer Cibacron Blue 3GA (CB 3GA) on contractions of the,rat vas deferens (RVD) elicited by alpha,beta-methylene ATP (alpha,beta-MeATP), mediated by P2X(1)-receptors, and relaxations of the carbachol-precontracted guinea pig taenia coli elicited by adenosine 5'-O-(2-thiophosphate) (ADPOS), mediated by P2Y(1)-like-receptors. All compounds inhibited the alpha,beta-MeATP induced contraction of the RVD and the ADPbetaS induced relaxation of the carbachol precontracted guinea-pig taenia coli. The IC50-values at P2X(1)-R were 9.1 muM for CB 3GA, 28.4 muM for RB 2, 19.7 muM for RB 2 meta, and 35.5 muM for RB 2 para. The IC50-values at P2Y(1)-like-R were 17.4 muM for CB 3GA, 7.7 muM for RB 2, 12.0 muM for RB 2 meta, and 2.6 muM for RB 2 para. The results clearly show that neither RB 2 as a mixture nor the pure ortho and meta isomer are P2Y(1)-like- versus P2X(1)-selective antagonists. In contrast the pure para-isomer of RB 2 is a moderately P2Y(1)-like- versus P2X(1)-selective antagonist. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.

  DOI：

  10.1016/s0223-5234(02)01449-6

文献信息

• Food intake, body weight and glucose metabolism regulation by modulation of P2Y6 receptor signaling
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP3002010A1

  公开（公告）日：2016-04-06

  The present invention is related to compound capable of regulating the activity of P2Y purinoceptor 6 signaling pathway, especially to compounds for inhibition of P2Y purinoceptor 6 polypeptide or inactivation, degradation, downregulation or intercalation of a nucleic acid encoding P2Y purinoceptor 6 or downregulation of P2Y purinoceptor 6 signaling pathway for the treatment of diseases related to energy balance as well as carbohydrate metabolism and homeostasis, preferably glucose metabolism and homeostasis. The present is also related to compounds for activation of P2Y purinoceptor 6 polypeptide or upregulation or modification for advanced transcriptional activity of a nucleic acid encoding P2Y purinoceptor 6, upregulation of P2Y purinoceptor 6 signaling pathway for gaining weight or for the treatment of diseases related to energy balance and carbohydrate metabolism and homeostasis. The invention is further related to methods of identifying said compounds suitable for the treatment of diseases related to energy balance and carbohydrate metabolism and homeostasis. The invention is further related to methods of treatment and diagnosis of diseases related to energy balance and carbohydrate metabolism and homeostasis and associated complications.

  本发明涉及能够调节 P2Y 嘌呤受体 6 信号通路活性的化合物，特别是用于抑制 P2Y 嘌呤受体 6 多肽或使编码 P2Y 嘌呤受体 6 的核酸失活、降解、下调或插入或下调 P2Y 嘌呤受体 6 信号通路的化合物，以治疗与能量平衡以及碳水化合物代谢和稳态有关的疾病，优选葡萄糖代谢和稳态。本发明还涉及用于激活 P2Y 嘌呤受体 6 多肽或上调或修饰编码 P2Y 嘌呤受体 6 的核酸的高级转录活性、上调 P2Y 嘌呤受体 6 信号通路的化合物，以增加体重或治疗与能量平衡和碳水化合物代谢及平衡有关的疾病。本发明进一步涉及鉴定所述化合物是否适用于治疗与能量平衡和碳水化合物代谢及平衡有关的疾病的方法。本发明进一步涉及治疗和诊断与能量平衡和碳水化合物代谢及稳态相关疾病及相关并发症的方法。
• Methods for coating surfaces with antimicrobial agents
  申请人：The Board of Regents of the University of Texas System

  公开号：US10589003B2

  公开（公告）日：2020-03-17

  Disclosed are methods for coating or impregnating a surface with an antimicrobial agent that involve contacting the surface with a composition that includes an antimicrobial agent and a solvent, and curing the surface by applying heat. Also disclosed are methods for reducing the risk of development or progression of an infection in a subject in need of a medical device, that involve coating or impregnating a surface of the medical device with an antimicrobial agent and then curing the surface by applying heat, wherein the risk of development or progression of an infection is reduced.

  本发明公开了用抗菌剂涂覆或浸渍表面的方法，包括用包括抗菌剂和溶剂的组合物接触表面，并通过加热固化表面。还公开了降低需要使用医疗器械的受试者发生或恶化感染风险的方法，包括用抗菌剂涂覆或浸渍医疗器械表面，然后通过加热固化表面，从而降低发生或恶化感染的风险。
• Treating compositions with lactoferrin
  申请人：——

  公开号：US20020160941A1

  公开（公告）日：2002-10-31

  Reducing the microbial contamination of a composition by treating with lactoferrin.

  用乳铁蛋白处理，减少成分中的微生物污染。
• Methods of using primer molecules for enhancing the mechanical performance of tissue adhesives and sealants
  申请人：Stedronsky R. Erwin

  公开号：US20050129745A1

  公开（公告）日：2005-06-16

  The present invention concerns novel methods for enhancing the mechanical performance of tissue adhesives and sealants which comprises employing a primer molecule in association with a tissue adhesive or sealant, wherein the primer molecule serves to enhance the strength of the interface between the tissue and the adhesive matrix. The primer molecules described herein function to interact with a protein present in the tissue, thereby altering its characteristics to make it more amenable to bonding with the adhesive matrix. Primer molecules may be applied to the tissue independently from the tissue adhesive or sealant or may be mixed with the tissue adhesive or sealant prior to application to the tissue.

  本发明涉及提高组织粘合剂和密封剂机械性能的新方法，包括使用与组织粘合剂或密封剂相关的引物分子，其中引物分子的作用是提高组织与粘合剂基质之间界面的强度。本文所述的引物分子的作用是与组织中的蛋白质相互作用，从而改变其特性，使其更适于与粘合剂基质粘合。底物分子可独立于组织粘合剂或密封剂应用于组织，也可在应用于组织之前与组织粘合剂或密封剂混合。
• ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0525073A1

  公开（公告）日：1993-02-03

表征谱图